XBP1 and breast carcinoma: As compared to the XBP1-CTL control, lenalidomide-treated XBP1-CTL (n=3) showed increased IFN-γ production in response to HLA-A2+ MDA-MB231 (breast cancer), Panc1 (pancreatic cancer) or SW480 (colon cancer) cells (Figure 4A).